EN | UA
EN | UA

Help Support

Back

Induction, randomized withdrawal, and retreatment of abrocitinib in atopic dermatitis people

Induction, randomized withdrawal, and retreatment of abrocitinib in atopic dermatitis people Induction, randomized withdrawal, and retreatment of abrocitinib in atopic dermatitis people
Induction, randomized withdrawal, and retreatment of abrocitinib in atopic dermatitis people Induction, randomized withdrawal, and retreatment of abrocitinib in atopic dermatitis people

A phase III trial examined the maintenance of abrocitinib-elicited response with continuous abrocitinib therapy, dose reduction or withdrawal, and response to therapy reintroduction after the flare. 

See All

Key take away

The findings from JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN study showed that most people suffering from moderate-to-severe atopic dermatitis who initially respond to abrocitinib maintain response with reduced dosing. Also, abrocitinib + topical therapy effectively recaptures response following flaring. 

Background

A phase III trial examined the maintenance of abrocitinib-elicited response with continuous abrocitinib therapy, dose reduction or withdrawal, and response to therapy reintroduction after the flare. 

Method

Subjects with atopic dermatitis who responded to open-label abrocitinib 200 mg monotherapy for twelve weeks were randomized to abrocitinib (100 or 200 mg) or placebo for about forty weeks. Rescue treatment (abrocitinib 200 mg+ topical therapy) was given to people experiencing flares. The loss of response requiring rescue medication during the maintenance period was the major outcome.

Result

Out of 1233 people, 798 responders to induction (64.7%) were randomly allocated. Table 1 shows the flare probability in the study groups during maintenance. Among people with flare in the study groups, the percentage of people regaining investigator global assessment (IGA) 0/1 response and eczema area and severity index (EASI) response with rescue treatment is shown in Table 1.


During maintenance, 54% and 63.2% of subjects receiving abrocitinib 100 and 200 mg, respectively, reported adverse events.

Conclusion

Induction therapy with abrocitinib is effective in atopic dermatitis patients. Most responders continuing abrocitinib therapy didn't flare. Rescue therapy with the combination of abrocitinib and topical therapy effectively recaptured the responses.

Source:

The Journal of the American Academy of Dermatology

Article:

Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial

Authors:

Andrew Blauvelt et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: